Nike stock rises after quarterly results beat estimates, amid ‘progress’ on efforts to reignite better growth

Date:

Share post:




Shares of Nike Inc. rose after hours on Thursday, after the sneaker maker reported fiscal third-quarter results that beat expectations and management said it was “encouraged” by the company’s efforts to focus on newer products and deliver better growth.



Source link

Alexandra Williams
Alexandra Williams
Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Recent posts

Related articles

Marriage proposals are still falling but should bottom this year, Signet says

Diamond seller Signet Jewelers’ stock tumbled Thursday, after the parent of Kay Jewelers, Zales and Jared jewelry-store...

Tommy Bahama maker says shoppers are still ‘more cautious than originally anticipated,’ but cites this improvement

Shares of Oxford Industries Inc. fell after hours on Wednesday after the owner of the Tommy Bahama...

Oil prices edge lower after Monday bounce; OPEC leaves forecasts unchanged

Oil futures were slightly lower Tuesday, consolidating after a large bounce the previous session as investors weighed...

OpenAI taps veteran of Nextdoor, Square as new CFO, raising speculation about IPO

Artificial-intelligence developer OpenAI said Monday that Sarah Friar would become its next chief financial officer, as it...

Fed won’t move interest rates next week, but meeting will still be a feast for economists

The Federal Reserve is widely expected keep its benchmark interest rate steady at the end of their...

Possible Trump pick for Treasury lays out 3-point economic plan that calls for deregulation, lower deficit

Hedge-fund manager Scott Bessent — viewed as in the running to become Treasury secretary in a second...

Gold suffers a ’double whammy’: strong U.S. jobs growth and pause in China buying

Gold futures were on track to post their lowest finish in about a month on Friday, pressured...

Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers 

When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental...